Cholesterol and Heart Risk Beyond the Headlines

Edited and Approved by Stephen C. Rose, PhD, MS

Cholesterol advice can sound contradictory. Eat fewer eggs. Pay more attention to metabolic health. Lower LDL. Be wary of medication. The useful response is to separate three questions: what causes artery disease, what predicts an individual’s risk, and what treatments actually improve outcomes. These questions overlap, but they are not interchangeable. Good prevention considers the whole person while taking the evidence about LDL seriously.

Why LDL still matters

Cholesterol is essential to the body. LDL particles carry cholesterol through the bloodstream, and LDL cholesterol, usually abbreviated LDL-C, measures the cholesterol they contain. Their normal biological role does not make excessive exposure harmless. Evidence from genetics, population studies, and treatment trials consistently links greater cumulative LDL exposure with atherosclerosis, the buildup of plaque in artery walls. This supports a causal role, beyond a simple statistical association. [1]

Inflammation and metabolic health also matter. They do not cancel the effects of cholesterol-carrying particles. Nor does a high LDL result guarantee a heart attack. Risk factors change probabilities; they do not predict every person’s future. The relevant question is how much risk is present, over what period, and how much of it can reasonably be reduced.

Food cholesterol and blood cholesterol are connected but different

Cholesterol on a food label does not translate directly into the same increase in blood cholesterol. The body adjusts its own production and absorption, and responses vary. A 2022 review emphasized these compensatory mechanisms and described favorable changes in some lipoprotein measurements with egg consumption. It was a review of multiple studies, not one definitive experiment proving that eggs prevent heart attacks. [2]

Other evidence is less reassuring about unlimited intake. An American Heart Association advisory found that most intervention meta-analyses linked cholesterol intake above usual amounts with higher total or LDL cholesterol. It favored an overall eating pattern rich in vegetables, fruits, whole grains, nuts, and other heart-supporting foods. Removing a single numerical intake limit does not establish that every amount suits every person. [3]

The practical issue is the whole meal and the person eating it. An egg alongside vegetables is a different dietary pattern from eggs routinely served with butter and processed meat. A blanket instruction that no clinician should ever advise limiting eggs goes beyond the evidence. Dietary advice should account for the complete diet and the person’s lipid response.

What treatment trials actually show

One frequently cited challenge comes from the Minnesota Coronary Experiment. A reanalysis found that replacing saturated fat with corn oil and corn-oil margarine lowered cholesterol without showing a survival benefit. An association between larger cholesterol declines and higher mortality also appeared. However, participants were randomized to diets, not to the size of their cholesterol decline. That association does not establish that lowering cholesterol caused the deaths. This historical dietary experiment also did not test statins. [4]

The broader dietary evidence deserves attention too. A 2020 Cochrane review found moderate-certainty evidence that reducing saturated fat for at least two years lowered combined cardiovascular events by about 17%, while showing little or no effect on overall mortality. Fewer cardiovascular events and longer survival are different outcomes; a study can show one without demonstrating the other. [5]

For statins, the evidence is stronger than the suggestion that lowering LDL generally fails to prevent heart attacks. A meta-analysis of 26 randomized trials involving roughly 170,000 participants found about a 22% relative reduction in major vascular events for each 1 mmol/L, approximately 39 mg/dL, reduction in LDL. All-cause mortality was also reduced. These findings reflect treatment comparisons, which are more informative about treatment effects than associations within a group of patients. [6]

Nonstatin evidence points in the same direction. In FOURIER, adding evolocumab to statins in people with established cardiovascular disease lowered median LDL to 30 mg/dL. Over a median 2.2 years, the broad cardiovascular endpoint occurred in 9.8% receiving evolocumab versus 11.3% receiving placebo. That is an absolute difference of 1.5 percentage points, or about 15 fewer events per 1,000 treated people. It does not mean everyone benefited, and the original trial did not establish a mortality reduction. [7]

The right goal depends on the person

An LDL goal below 55 mg/dL is not a universal definition of normal. The 2026 US dyslipidemia guideline recommends that goal for people with established atherosclerotic cardiovascular disease at very high risk. It recommends less intensive goals in other risk groups. It also replaces the older Pooled Cohort Equations with PREVENT for appropriate primary-prevention risk assessment. Describing today’s approach as an automatic prescription based on an older 7.5% threshold is outdated. [8]

Age influences cardiovascular risk for good reason, but a risk estimate should begin a conversation. Expected benefit, health status, competing illnesses, treatment burden, and preferences all belong in that conversation. A percentage without a time horizon or a clear outcome is incomplete information.

Ask for absolute benefit. In a hypothetical example, a treatment that reduces risk by 20% relatively would lower a 10% risk to 8%, an absolute reduction of two percentage points. The same relative reduction applied to a 2% risk produces a 1.6% risk, an absolute reduction of 0.4 points. These are illustrations, not personal estimates. They explain why baseline risk changes the value of treatment.

Why reassuring examples can mislead

A study of 168 Sardinian nonagenarians reported median total cholesterol values of 199.5 mg/dL in men and 202.5 mg/dL in women. Those were not LDL values, despite how they have been described online. Higher LDL was associated with longer survival in this selected elderly group. That observation deserves study, but it cannot establish that raising LDL prolongs life or that lowering it harms younger adults. [9]

Likewise, a registry found that almost half of patients hospitalized with coronary artery disease had admission LDL below 100 mg/dL. The group was not limited to emergency-room heart attacks. An admission measurement cannot reconstruct lifelong exposure, and studying only hospitalized patients provides no comparison with people who avoided hospitalization. This finding does not make LDL unimportant. [10]

Very high LDL in lean people eating ketogenic diets remains an unresolved clinical question. A 2024 study comparing 80 diet-associated cholesterol hyper-responders with 80 matched controls found no significant difference in coronary plaque. Its selected sample and observational design do not establish lifelong safety. [11] A separate 2025 longitudinal KETO-CTA paper was retracted in 2026 because methodological problems affected data reliability. That retraction concerns the later paper, not the 2024 comparison. [12]

Take side effects seriously without inventing them

The claim that aggressive cholesterol lowering causes Alzheimer’s disease is not supported by randomized evidence. A 2025 meta-analysis included 139,169 participants in trials reporting dementia or cognitive impairment and found no statistically significant difference between lipid-lowering therapy and controls. Average follow-up was about three years, so it cannot settle every question about decades of exposure. It also did not prove that these medicines prevent dementia. [13]

Statins do have adverse effects. A large analysis of blinded trials found a small excess of muscle pain or weakness, concentrated in the first treatment year; most reported muscle symptoms were not caused by the drug. [14] Another trial meta-analysis confirmed a dose-dependent increase in diabetes diagnoses. With low- or moderate-intensity statins, the average absolute excess was about 0.12 percentage points per year. Individual risk varies. [15]

Symptoms warrant assessment and a workable treatment plan. Diet, physical activity, and attention to other risk factors remain important whether medication is used or not. The strongest approach combines evidence about LDL with an honest discussion of expected benefit and harms. Ask what outcome a recommendation is intended to prevent, what benefit is realistic for you, and how the plan will be reassessed.

References

[1] Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. European Heart Journal. 2017;38:2459–2472. doi:10.1093/eurheartj/ehx144.

[2] Fernandez ML, Murillo AG. Is There a Correlation between Dietary and Blood Cholesterol? Evidence from Epidemiological Data and Clinical Interventions. Nutrients. 2022;14:2168. doi:10.3390/nu14102168.

[3] Carson JAS, Lichtenstein AH, Anderson CAM, et al. Dietary Cholesterol and Cardiovascular Risk: A Science Advisory From the American Heart Association. Circulation. 2020;141:e39–e53. doi:10.1161/CIR.0000000000000743.

[4] Ramsden CE, Zamora D, Majchrzak-Hong S, et al. Re-evaluation of the traditional diet-heart hypothesis: analysis of recovered data from Minnesota Coronary Experiment (1968–73). BMJ. 2016;353:i1246. doi:10.1136/bmj.i1246.

[5] Hooper L, Martin N, Jimoh OF, et al. Reduction in saturated fat intake for cardiovascular disease. Cochrane Database of Systematic Reviews. 2020;8:CD011737. doi:10.1002/14651858.CD011737.pub3.

[6] Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–1681. doi:10.1016/S0140-6736(10)61350-5.

[7] Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. New England Journal of Medicine. 2017;376:1713–1722. doi:10.1056/NEJMoa1615664.

[8] Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. Circulation. 2026;153:e1154–e1276. doi:10.1161/CIR.0000000000001423.

[9] Errigo A, Dore MP, Portoghese M, Pes GM. The Cholesterol Paradox in Long-Livers from a Sardinia Longevity Hot Spot (Blue Zone). Nutrients. 2025;17:765. doi:10.3390/nu17050765.

[10] Sachdeva A, Cannon CP, Deedwania PC, et al. Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines. American Heart Journal. 2009;157:111–117.e2. doi:10.1016/j.ahj.2008.08.010.

[11] Budoff M, Manubolu VS, Kinninger A, et al. Carbohydrate Restriction-Induced Elevations in LDL-Cholesterol and Atherosclerosis: The KETO Trial. JACC: Advances. 2024;3:101109. doi:10.1016/j.jacadv.2024.101109.

[12] Soto-Mota A, Norwitz NG, Manubolu VS, et al. Longitudinal Data from the KETO-CTA Study: Plaque Predicts Plaque, ApoB Does Not: JACC Adv. 2025;4(7):101686. Retraction notice. JACC: Advances. 2026;5:102824. doi:10.1016/j.jacadv.2026.102824.

[13] Reddin C, Stankard A, Chan KY, et al. Association of lipid-lowering therapy with dementia and cognitive outcomes: a systematic review and meta-analysis. Age and Ageing. 2025;54:afaf219. doi:10.1093/ageing/afaf219.

[14] Cholesterol Treatment Trialists’ Collaboration. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. Lancet. 2022;400:832–845. doi:10.1016/S0140-6736(22)01545-8.

[15] Cholesterol Treatment Trialists’ Collaboration. Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis. Lancet Diabetes and Endocrinology. 2024;12:306–319. doi:10.1016/S2213-8587(24)00040-8.